In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications

被引:103
作者
McGinnis, MR
Pasarell, L
机构
[1] Univ Texas, Med Branch, Dept Pathol, Galveston, TX 77555 USA
[2] WHO, Collaborat Ctr Trop Dis, Galveston, TX 77555 USA
关键词
D O I
10.1128/JCM.36.8.2353-2355.1998
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The in vitro susceptibilities of three hundred eighty-one isolates representing two classes, five orders, nine families, 30 genera, and 51 species of ascomycetous fungi to voriconazole, itraconazole, and amphotericin B were tested by using a modification of the National Committee for Clinical Laboratory Standards M27-A reference method. For those fungi of known phylogenetic relatedness, drug MICs were consistently low for isolates among all clades, except for members of the family Microascaceae. The highest MICs of all drugs tested were consistently for the Microascaceae, supporting the observation of fungal phylogeny and corresponding susceptibility to antifungal drugs. Itraconazole and voriconazole have a broad range of activity against phylogenetically similar agents of hyalohyphomycosis, phaeohyphomycosis, chromoblastomycosis, and mycetoma.
引用
收藏
页码:2353 / 2355
页数:3
相关论文
共 11 条
[1]  
ALILOU M, 1977, Bulletin de la Societe Francaise de Mycologie Medicale, V6, P227
[2]   In vitro studies of two triazole antifungal agents (Voriconazole [UK-109,496] and fluconazole) against Candida species [J].
Barry, AL ;
Brown, SD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) :1948-1949
[3]   In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens [J].
Espinel-Ingroff, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (01) :198-202
[4]   In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. [J].
Marco, F ;
Pfaller, MA ;
Messer, S ;
Jones, RN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (01) :161-163
[5]  
Mcginnis M. R., 1996, ANTIBIOTICS LAB MED, V4th, P176
[6]   In vitro evaluation of voriconazole against some clinically important fungi [J].
McGinnis, MR ;
Pasarell, L ;
Sutton, DA ;
Fothergill, AW ;
Cooper, CR ;
Rinaldi, MG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (08) :1832-1834
[7]  
National Committee for Clinical Laboratory Standards, 1997, M27A NAT COMM CLIN L
[8]   VIABILITY OF FUNGAL CULTURES MAINTAINED AT -70-DEGREES-C [J].
PASARELL, L ;
MCGINNIS, MR .
JOURNAL OF CLINICAL MICROBIOLOGY, 1992, 30 (04) :1000-1004
[9]   AN EVALUATION OF STRAW-EXTRACT AGAR MEDIA FOR THE GROWTH AND SPORULATION OF MADURELLA-MYCETOMATIS [J].
RAJENDRAN, C ;
BABY, A ;
KUMARI, S ;
VERGHESE, T .
MYCOPATHOLOGIA, 1991, 115 (01) :9-12
[10]  
Weete JD., 1996, Biochemistry and Molecular Biology, P421, DOI DOI 10.1007/978-3-662-10367-8_20